Alteogen Inc. announced that it has completed phase 1 clinical trial of Eylea Biosimilar (ALT-L9). The clinical trial was conducted at 4 major hospitals in Korea: Asan Hospital, Seoul National University Bundang Hospital, Samsung Seoul Hospital, and Severance Hospital. The company has strengthened competitiveness through formulation patent registered in US, EU and Japan and filing of a process patent for PCT application. Eylea original product and the company’s Eylea biosimilar (ALT-L9) were randomly assigned 1:1 to 28 patients with neovascular (wet) age-related macular degeneration; the study design was double blinded, active control, and parallel. No adverse drug-related reactions were observed in both groups and showed similar improvement effects in best corrected visual acuity (BCVA) and central subfield thickness (CST). In this phase 1 clinical trial, the company confirmed the safety and efficacy of ALT-L9 were similar to that of Eylea. The company intends to prove the similarity of ALT-L9 with Eylea through a registrational phase 3 clinical trial. The results from the phase 1 trial in Korea will support the design of the phase 3 trial and potentially provide a path to a shorter phase 3 trial.